The Indian markets have witnessed renewed investor interest across pharma, speciality chemicals, and exchange-traded services, with recent corporate earnings providing both optimism and caution. ET Now spoke with Amnish Aggarwal from Prabhudas Lilladher, who shared his insights on sector trends and specific stock preferences.

Pharma: Numbers Improving, Select Names Preferred

When asked about the pharma sector and potential investment preferences beyond CDMOs. Aggarwal noted, “Pharma in the past, say, if you look at last 10-15 days, it has been sort of coming back and the main reason was that the market was a lot jittery at that point of time and also the pharma valuations have been relative to the valuations at which they are quoting at. However, if you look at the numbers of the past few days, the numbers have been good. If you look at particularly the MNC pharma companies like GSK or Pfizer, the numbers are quite decent and the stocks are also not expensive. But having said that, our current preference still revolves around, say, names like Sun Pharma where the numbers are okayish and if you look at the overall scenario, the pharma as a pack continues to look good.”

Speciality Chemicals: Growth Potential with Patience
On speciality chemicals, Aggarwal emphasized a company-specific approach. “You see in speciality chemicals one has to look at from company to company. Navin Fluorine, particularly, the numbers have been pretty decent. But if you look at their future expansion plans and where the stock is currently poised, it is already trading at something like 37-38 times on FY28. But having said that, if the actual impact of this US trade deal plays out over a period of time, then there could be more growth opportunities for many of these chemical companies, but it is not something which is going to happen in a day. It will take its own sweet time.”

Currency and Operational Efficiencies
Addressing currency tailwinds and operational efficiency in pharma, Aggarwal remarked, “A currency tailwind first of all one has to look at that rupee used to be 88-89 and now whether it is going back to 89 I think I am particularly doubtful about it because it is definitely not likely to go there, it might not be 92 in the immediate term.”

“Now the second part is in many of these companies I would say there is a lot of gains from stable raw material prices as also the efficiency gains. So, to that extent the numbers of many of these pharma companies they seem sustainable. One has to separate between the generic pharma companies and the companies which are having more domestic exposure because in case of many of these generic pharma companies a couple of molecules which were actually driving the sales whether it is Zydus, whether it is I believe Dr Reddy’s and also those molecules they are not likely to get benefit from that, but definitely the numbers have been pretty decent for most of the names and the valuations are not expensive at this point of time,” he added.
Exchange Performance: BSE Margins and NSE Listing Impact
Regarding BSE’s recent performance, Aggarwal explained, “You see that if you look at BSE, then their profitability and margin they have improved over the quarters. But having said that the F&O segment is some bit, I would say, under pressure and the market is also not in that sort of a zone from the last, say, three months or so. So that is getting reflected in the performance of BSE because in exchanges it is highly, I would say, your operating leverage is very high which acts on both sides. So, last quarter the markets in general were very jittery. “Smallcap and midcaps were down quite a bit where BSE is also having, I would say, the bigger share because many of these older smallcap, midcaps they are listed only in BSE and also the overall sentiment actually plays out a role. So, it is just a passing phase and the things will rebound as we go along,” he added.

On the potential impact of the NSE IPO, Aggarwal added, “Difficult to say at this point of time, but if you look at global exchanges, so they actually get a valuation of 30 to 40 times very easily. So, is BSE overly expensive, that does not look at this point of time. But having said that, it will also be a function of how your NSE gets listed that is one and secondly in terms of volume you will also because once NSE gets listed, it will be listed only on BSE. So to that extent that, it will also be an advantage to BSE to some extent.”

EMS Sector: Divergence but Select Leaders Stand Out
Turning to EMS (Electronics Manufacturing Services), Aggarwal observed that numbers remain volatile. “The numbers on the EMS side, as you said, they have been very volatile because the companies have been either reporting very high numbers or where there are misses also, the misses have been very significant. Now, if you look at the Amber’s numbers yesterday, the numbers were quite good and if the summer season next time also remain strong as is expected for the air conditioners, I think the Amber as such should do well,” he said.

“Even in case of Dixon the numbers were pretty strong. So, Amber and Dixon which have been there listed from quite some time, where the numbers are strong and the valuations are not as expensive, they still seem to be better placed than some of the other companies,” he added.

The Thai baht rose 1.3% to 31.2 per dollar, boosted by the Bhumjaithai Party’s election victory, securing 191 seats and enhancing market confidence and policy continuity in Thailand.

---

Key Points

• The Thai baht increased by 1.3% to 31.2 per dollar on Monday, recovering from previous losses and reaching a one-week high due to improved market sentiment following the Bhumjaithai Party’s election win.
• The ruling Bhumjaithai Party secured 191 out of 500 seats in the House of Representatives, nearly tripling its 2023 count, enhancing market confidence and reducing risks of political instability.
• This election outcome suggests policy continuity regarding social handouts and budget approvals, while the pro-democracy People’s Party, which led in pre-election surveys, is projected to win 115 seats.

Market Sentiment Improvement

The Thai baht rose by 1.3% to 31.2 per dollar on Monday, recovering from previous losses and reaching a high not seen in over a week. This rebound can be largely attributed to enhanced market sentiment following the substantial election success of the Bhumjaithai Party. As Thailand’s ruling conservative party, the Bhumjaithai Party has made a significant impact by winning 191 of the 500 seats in the House of Representatives, a notable increase nearly triple that of their 2023 performance. This solid victory has instilled confidence among investors, signaling a more stable political environment.

Implications for Political Stability

With a solid electoral win, the Bhumjaithai Party is predicted to reduce the risks associated with political deadlock or instability. A robust showing by Prime Minister Anutin Charnvirakul and his anticipated coalition partners suggests a more cohesive governing body and the potential for policy continuity. This outcome is not just about immediate political dynamics; it enables the continuation of the party’s social handouts and lays the groundwork for the approval of a new budget. As the electorate embraces this new direction, hopes for progress in governance and economic policy remain optimistic.

Opposition Landscape Overview

On the other hand, the pro-democracy People’s Party, which had been a front-runner in pre-election polls, is expected to secure 115 seats. Despite the party’s inability to match the Bhumjaithai Party’s success, their presence will likely contribute to a more diverse political discourse in Thailand. The results highlight a shifting electoral landscape where traditional party dominance faces challenges from emerging political entities. In summary, the elections have not only altered the composition of Thailand’s legislature but also the broader implications for future governance and public policy.

Other People are Reading

Shares of Navin Fluorine International rallied after 3% to Rs 6,6824 after the company reported a robust set of figures for the December quarter of financial year 2026. Net profit rose to Rs 185.4 crore in the quarter, up an impressive 122% from Rs 83.6 crore in the corresponding period last year.

Revenue from operations increased 47.2% YoY to Rs 892.3 crore compared with Rs 606.2 crore a year earlier.

Operating performance improved significantly during the quarter. EBITDA climbed to Rs 307.4 crore from Rs 147.3 crore in the year-ago period, while the EBITDA margin expanded to 34.4% from 24.3%, reflecting stronger operating leverage and a favourable business mix.

As for the revenue split, HPP (high-performance products), which includes refrigerants and inorganic fluorides, reported a 35% increase in revenue at Rs 412 crore in Q3FY26. The specialty chemicals business recorded a 60% increase to Rs 354 crore, while the CDMO business rose 61% in revenue terms to Rs 127 crore, the company’s regulatory filing showed.

Also Read | Quant MF cuts gold, silver exposure near peak levels in multi-asset fund

The HPP segment reported revenue growth during the period, supported by higher realisations along with increased volumes. The AHF capex was commissioned in Q4FY26 and dispatches have already commenced. It also noted that the pricing environment for HFC continues to remain constructive.
The specialty chemicals business continues to maintain a strong product pipeline, with scale-up underway in existing molecules and new molecule launches planned. De-bottlenecking of the MPP capacity at the Dahej facility is progressing as scheduled and is expected to be commissioned in Q3FY27. The segment delivered its highest-ever quarterly performance and the outlook remains positive, backed by strong order visibility for Q4 and beyond.The CDMO business maintained its momentum with robust order visibility. The company highlighted progress in its strategy, focusing on a balanced portfolio with a mix of early-stage and late or commercial-stage molecules. Supplies for a material order to one EU major have been completed and discussions for future supplies are ongoing, while another EU major has placed a scale-up order scheduled for Q4 supplies.

Navin Fluorine is a specialty fluorochemicals manufacturer serving global customers across pharmaceuticals, agrochemicals, specialty chemicals and high-performance materials.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times.)